Thiopyrimidinecarboxamide for use in treating pulmonary disease
There is disclosed is a method of treating a pulmonary disease using a pyrimidinecarboxamide compound, and a pharmaceutical composition suitable for inhalation comprising the pyrimidinecarboxamide compound.
1. A method for treating a CXCR1/2 chemokine mediated disease, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula SX-682
or a pharmaceutically acceptable salt or solvate thereof, wherein the CXCR1/2 chemokine mediated disease is a pulmonary disease selected from asthma, cystic fibrosis, adult respiratory disease, airway hyperresponsiveness, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, cor pulmonale, dyspnea, emphysema, hyperinflation, hypoxemia, hyperoxia-induced inflammations, hypoxia, surgical lung volume reduction, pulmonary fibrosis, pulmonary hypertension, small airway disease, or ventilation-perfusion mismatching.
2. The method of claim 1 , wherein the compound or a pharmaceutically acceptable salt or solvate thereof is administered orally, transdermally, parenterally, intranasally, or by inhalation.
3. The method of claim 2 , wherein the compound or a pharmaceutically acceptable salt or solvate thereof is administered by inhalation.
4. The method of claim 1 , wherein the compound or a pharmaceutically acceptable salt or solvate thereof is co-administered with a compound selected from glucocorticoids, 5-lipoxygenase inhibitors, beta-2 adrenoceptor agonists, muscarinic M1 antagonists, muscarinic M3 antagonists, muscarinic M2 agonists, NK3 antagonists, LTB4 antagonists, cysteinyl leukotriene antagonists, bronchodilators, PDE4 inhibitors, PDE inhibitors, elastase inhibitors, MMP inhibitors, phospholipase A2 inhibitors, phospholipase D inhibitors, histamine H1 antagonists, histamine H3 antagonists, dopamine agonists, adenosine A2 agonists, NK1 and NK2 antagonists, GABA-β agonists, nociceptin agonists, expectorants, mucolytic agents, decongestants, antioxidants, anti-IL-8 antibodies, anti-IL-5 antibodies, anti-IgE antibodies, anti-TNF antibodies, IL-10, adhesion molecule inhibitors, and growth hormones.
5. The method of claim 1 , wherein the compound or a pharmaceutically acceptable salt or solvate thereof is administered in a 0.01 mg to 1000 mg dose.
6. The method of claim 1 , wherein the compound or a pharmaceutically acceptable salt or solvate thereof is administered in a 0.01 mg to 7500 mg dose.
7. The method of claim 1 , wherein the compound or a pharmaceutically acceptable salt or solvate thereof is administered in a 0.01 mg to 500 mg dose.
8. The method of claim 1 , wherein the compound or a pharmaceutically acceptable salt or solvate thereof is administered orally or by inhalation in a daily, twice-weekly or once-weekly dose of 0.04 mg to 4000 mg, given in two to four divided doses or as a single dose.
9. The method of claim 8 , wherein the dose of the compound or a pharmaceutically acceptable salt or solvate thereof is 10 mg to 2000 mg.
10. The method of claim 8 , wherein the dose of the or a pharmaceutically acceptable salt or solvate thereof is 10 mg to 1000 mg.
11. The method of claim 8 , wherein the dose of the compound or a pharmaceutically acceptable salt or solvate thereof is 50 mg to 600 mg.
12. The method of claim 1 , wherein the pulmonary disease is asthma.
13. The method of claim 1 , wherein the pulmonary disease is cystic fibrosis or adult respiratory disease.
14. The method of claim 1 , wherein the pulmonary disease is a selected from airway hyperresponsiveness, bronchiectasis, bronchiolitis, bronchiolitis obliterans, chronic bronchitis, cor pulmonale, dyspnea, emphysema, hyperinflation, hypoxemia, hyperoxia-induced inflammations, hypoxia, surgical lung volume reduction, pulmonary fibrosis, pulmonary hypertension, small airway disease, or ventilation-perfusion mismatching.
15. A pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula SX-682
or a pharmaceutically acceptable salt or solvate thereof, wherein the pharmaceutical formulation is suitable for inhalation to a subject having a pulmonary disease.
16. The pharmaceutical formulation of claim 15 , wherein the compound has a half-life in human plasma of greater than 200 minutes.
17. The pharmaceutical formulation of claim 15 , wherein the formulation is an aerosol preparation.
18. The pharmaceutical formulation of claim 17 , wherein the formulation is in combination with a pharmaceutically acceptable carrier.
19. The pharmaceutical formulation of claim 18 , wherein the pharmaceutically acceptable carrier is an inert compressed gas.
20. The pharmaceutical formulation of claim 15 , wherein the quantity of the compound in a unit dose of preparation is from 0.01 mg to 1000 mg.